Efficacy, Safety, and Biomarkers of Neoadjuvant Bevacizumab, Radiation Therapy, and Fluorouracil in Rectal Cancer: A Multidisciplinary Phase II StudyChristopher G. Willett, Dan G. Duda, Emmanuelle di Tomaso et al.|Journal of Clinical Oncology|2009Cited by 507
A Safety and Survival Analysis of Neoadjuvant Bevacizumab with Standard Chemoradiation in a Phase I/II Study Compared with Standard Chemoradiation in Locally Advanced Rectal CancerChristopher G. Willett, Dan G. Duda, Marek Ancukiewicz et al.|The Oncologist|2010Cited by 54
Abstract 5960: Targeting CDK8: A translatable therapeutic approach for fusion-positive aRMSSusu Zhang, Kimberly Stegmaier, Clare F. Malone et al.|Cancer Research|2024Cited by 0
Abstract A022-PR005: CDK8 Inhibition Releases the Muscle Differentiation Block in Fusion-Driven Alveolar RhabdomyosarcomaSusu Zhang, Kimberly Stegmaier, Brian Guedes et al.|Cancer Research|2025Cited by 0